Chinese-developed lung cancer treatment approved for NHS patients in England #coolchina
By CGTN
Community Score: 50% | 313 views | 2w
0 community ratings: null thumbs up, null thumbs down
A Chinese-developed immunotherapy for one of the most aggressive forms of lung cancer is set to become available on England's National Health Service, marking a milestone for both patients and China's rapidly growing pharmaceutical industry. The National Institute for Health and Care Excellence (NICE) has recommended Serplulimab (Hetronifly), developed by Shanghai-based biotechnology company Henlius, in combination with chemotherapy for eligible patients with extensive stage small cell lung cancer (SCLC). SCLC is an aggressive form of lung cancer with limited treatment options and a poor prognosis. #news #China #UK #science #research #cancer 📺 Subscribe to our YouTube channel and stay updated with our latest analysis and interviews:👇 https://www.youtube.com/channel/UCgrNz-aDmcr2uuto8_DL2jg 👈 Download our APP on Apple Store (iOS): https://itunes.apple.com/us/app/cctvnews-app/id922456579?l=zh&ls=1&mt=8 Download our APP on Google Play (Android): https://play.google.com/store/apps
Tags: CGTN, News, China, Current news, Chinese news, CGTN NEWS, cancer, technology, research, medicine
More from CGTN
- Jeffrey Sachs: US and Israel underestimated Iran — Score: 50%
- Key outcomes of the China-US economic, trade talks in Paris — Score: 50%
- Israeli Prime Minister posts video to prove he is alive #worldnow — Score: 50%
- China's Kuaizhou-11 Y7 rocket launches eight new satellites #coolchina — Score: 50%
- Trump says he 'demands' 7 countries escort ships through Strait of Hormuz #worldnow — Score: 50%
- Live ship tracking map showing the Strait of Hormuz — Score: 50%